19-28z CAR EBV-VST clinical trial design. (A) Patients in cohort 1 were treated with 1 to 3 cycles of 19-28z CAR EBV-VSTs after relapse after transplant, and patients in cohorts 2 and 3 were treated with 1 to 3 cycles of 19-28z CAR EBV-VSTs as consolidation with hematopoietic cell transplant. (B) Schema showing patients in each cohort along with their diagnosis and transplant donor type. B-NHL, B-cell non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia.